
Wearable Devices Can Predict Disease Activity in Inflammatory Bowel Disease Patients

Developed specifically to guide pharma looking to incorporate real world patient data, the second volume of our Device Census Report investigates the current wearable devices best suited for clinical research.
Litmus helps researchers better understand patients’ behavior and environment.
We use wearables data collected at the point of experience to guide management and to inform clinical trial endpoints.
Takeda Pharmaceuticals, along with Dr. David Rubin and his colleagues at the University of Chicago, are leveraging Litmus Health in a 500 patient study conducted over three years that is already producing exciting, publishable results.
We’re gathering data from smartphones, ePRO, and wearables to better understand the relationship between sleep, activity, and flares in Crohn’s and Colitis patients. Our ultimate goal is to use the models to accurately predict health outcomes.
Initial results have shown the potential to inform patient disease monitoring and management strategies. Dr. Rubin’s team and Litmus are now developing models capable of predicting IBD flares based on heart rate, sleep, and physical activity.
We believe quality of life is the ultimate endpoint, and we’re focused on helping investigators and their sponsors bring better drugs and therapeutics to market, faster.